NCT03113617
- Conditions
- Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma, Stage IV Prostate Adenocarcinoma
- Locations
-
- Stanford University, School of Medicine Palo Alto, California, United States
Clinical trial condition
Stage III Prostate Adenocarcinoma
Explore clinical trials studying Stage III Prostate Adenocarcinoma. Study availability and eligibility vary by location and protocol.
4 public trials
0 recruiting studies
Stage III Prostate Adenocarcinoma trial results
NCT02678351
- Conditions
- Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
- Locations
-
- Stanford University, School of Medicine Palo Alto, California, United States
NCT02472275
- Conditions
- Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
- Locations
-
- Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States
- Karmanos Cancer Institute at McLaren Northern Michigan - Petoskey Radiation Oncology Petoskey, Michigan, United States
- Karmanos Cancer Institute at McLaren Northern Michigan- Petoskey Medical Oncology Petoskey, Michigan, United States
Active, Not Recruiting
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
NCT02949284
- Conditions
- Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
- Locations
-
- Yale Cancer Center New Haven, Connecticut, United States
- Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States